Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Price:
46.31
USD
-1.51%
Market Closed
Market Cap:
$3.5B
Income Statement
Earnings Waterfall
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Income Statement
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Currency: USD
| Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
8
N/A
|
20
+157%
|
39
+95%
|
71
+84%
|
90
+27%
|
177
+97%
|
220
+24%
|
236
+7%
|
281
+19%
|
249
-11%
|
270
+9%
|
302
+12%
|
339
+12%
|
384
+13%
|
423
+10%
|
481
+14%
|
529
+10%
|
598
+13%
|
678
+13%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(5)
|
(9)
|
(13)
|
(16)
|
(20)
|
(23)
|
(26)
|
(28)
|
(31)
|
(33)
|
(37)
|
(42)
|
(53)
|
(61)
|
(68)
|
(74)
|
(75)
|
(78)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
5
N/A
|
15
+178%
|
29
+102%
|
57
+95%
|
74
+29%
|
157
+112%
|
197
+26%
|
211
+7%
|
252
+20%
|
218
-14%
|
237
+9%
|
265
+12%
|
297
+12%
|
332
+11%
|
362
+9%
|
413
+14%
|
455
+10%
|
523
+15%
|
600
+15%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||
| Operating Expenses |
(65)
|
(77)
|
(87)
|
(97)
|
(108)
|
(159)
|
(177)
|
(182)
|
(170)
|
(132)
|
(124)
|
(137)
|
(157)
|
(177)
|
(191)
|
(188)
|
(186)
|
(188)
|
(184)
|
(189)
|
(188)
|
(189)
|
(214)
|
(237)
|
(262)
|
(295)
|
(325)
|
(358)
|
(408)
|
(429)
|
(450)
|
(485)
|
(523)
|
|
| Selling, General & Administrative |
(9)
|
(11)
|
(13)
|
(16)
|
(22)
|
(26)
|
(30)
|
(33)
|
(35)
|
(35)
|
(36)
|
(40)
|
(45)
|
(57)
|
(70)
|
(79)
|
(86)
|
(88)
|
(90)
|
(93)
|
(98)
|
(105)
|
(110)
|
(120)
|
(129)
|
(139)
|
(152)
|
(164)
|
(168)
|
(173)
|
(177)
|
(180)
|
(196)
|
|
| Research & Development |
(56)
|
(66)
|
(74)
|
(80)
|
(87)
|
(133)
|
(147)
|
(148)
|
(135)
|
(97)
|
(88)
|
(98)
|
(112)
|
(120)
|
(121)
|
(109)
|
(99)
|
(91)
|
(81)
|
(79)
|
(65)
|
(60)
|
(70)
|
(70)
|
(76)
|
(87)
|
(88)
|
(96)
|
(112)
|
(105)
|
(99)
|
(97)
|
(97)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(9)
|
(13)
|
(17)
|
(24)
|
(24)
|
(34)
|
(47)
|
(57)
|
(69)
|
(85)
|
(97)
|
(128)
|
(151)
|
(174)
|
(208)
|
(230)
|
|
| Operating Income |
(65)
N/A
|
(77)
-17%
|
(87)
-13%
|
(97)
-11%
|
(108)
-12%
|
(159)
-47%
|
(177)
-11%
|
(182)
-2%
|
(170)
+6%
|
(132)
+23%
|
(124)
+6%
|
(137)
-10%
|
(157)
-15%
|
(177)
-13%
|
(186)
-5%
|
(173)
+7%
|
(157)
+10%
|
(131)
+17%
|
(109)
+16%
|
(32)
+70%
|
10
N/A
|
22
+124%
|
38
+74%
|
(19)
N/A
|
(25)
-31%
|
(31)
-21%
|
(28)
+10%
|
(26)
+5%
|
(46)
-74%
|
(16)
+65%
|
4
N/A
|
38
+753%
|
77
+102%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||
| Interest Income Expense |
1
|
1
|
2
|
3
|
5
|
6
|
7
|
7
|
6
|
5
|
4
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
5
|
7
|
9
|
9
|
9
|
10
|
9
|
9
|
10
|
10
|
12
|
|
| Pre-Tax Income |
(65)
N/A
|
(76)
-17%
|
(85)
-12%
|
(94)
-10%
|
(103)
-11%
|
(153)
-48%
|
(170)
-11%
|
(175)
-3%
|
(164)
+6%
|
(127)
+23%
|
(121)
+5%
|
(135)
-12%
|
(156)
-16%
|
(177)
-13%
|
(186)
-5%
|
(173)
+7%
|
(157)
+10%
|
(131)
+17%
|
(109)
+16%
|
(32)
+71%
|
11
N/A
|
25
+126%
|
43
+72%
|
(12)
N/A
|
(17)
-36%
|
(22)
-29%
|
(18)
+16%
|
(17)
+7%
|
(36)
-116%
|
(6)
+83%
|
14
N/A
|
49
+241%
|
89
+83%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
4
|
(2)
|
(5)
|
(5)
|
(8)
|
(3)
|
(2)
|
(1)
|
(3)
|
(3)
|
174
|
172
|
171
|
188
|
6
|
31
|
30
|
8
|
8
|
(7)
|
(11)
|
(9)
|
(13)
|
(30)
|
|
| Income from Continuing Operations |
(65)
|
(76)
|
(85)
|
(93)
|
(103)
|
(153)
|
(170)
|
(173)
|
(162)
|
(122)
|
(123)
|
(140)
|
(161)
|
(184)
|
(189)
|
(175)
|
(158)
|
(134)
|
(112)
|
143
|
183
|
196
|
231
|
(7)
|
14
|
9
|
(10)
|
(9)
|
(43)
|
(17)
|
5
|
36
|
59
|
|
| Net Income (Common) |
(65)
N/A
|
(76)
-17%
|
(85)
-12%
|
(93)
-10%
|
(103)
-11%
|
(153)
-48%
|
(170)
-11%
|
(173)
-2%
|
(162)
+6%
|
(122)
+24%
|
(123)
0%
|
(140)
-14%
|
(161)
-16%
|
(184)
-14%
|
(189)
-2%
|
(175)
+7%
|
(158)
+10%
|
(134)
+15%
|
(112)
+16%
|
143
N/A
|
183
+29%
|
196
+7%
|
231
+18%
|
(7)
N/A
|
14
N/A
|
9
-39%
|
(10)
N/A
|
(9)
+11%
|
(43)
-376%
|
(17)
+61%
|
5
N/A
|
36
+650%
|
59
+64%
|
|
| EPS (Diluted) |
-1.34
N/A
|
-1.55
-16%
|
-1.73
-12%
|
-1.9
-10%
|
-2.09
-10%
|
-2.95
-41%
|
-3.12
-6%
|
-3.14
-1%
|
-2.99
+5%
|
-2.23
+25%
|
-2.11
+5%
|
-2.11
N/A
|
-2.61
-24%
|
-2.7
-3%
|
-2.75
-2%
|
-2.56
+7%
|
-2.3
+10%
|
-1.94
+16%
|
-1.62
+16%
|
2.02
N/A
|
2.6
+29%
|
2.81
+8%
|
3.22
+15%
|
-0.11
N/A
|
0.2
N/A
|
0.12
-40%
|
-0.14
N/A
|
-0.12
+14%
|
-0.6
-400%
|
-0.22
+63%
|
0.06
N/A
|
0.45
+650%
|
0.75
+67%
|
|
Switch to:
Switch to:
See Also
Discover More
